期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 19, 期 1, 页码 E9-E11出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2018.10.002
关键词
CD38 antibodies; CMV; Infectious complication; Plasma cell dyscrasia; Viral infection
We report a case of symptomatic cytomegalovirus (CMV) reactivation upon initiation of daratumumab monotherapy treatment in a heavily pretreated patient with multiple myeloma (MM). In patients with MM, the risk of CMV reactivation is increased following autologous stem cell transplantation. Limited data is available on the incidence of CMV reactivation in patients with MM who did not receive a stem cell transplantation. To our knowledge, this is the first report of a symptomatic CMV reactivation during daratumumab monotherapy treatment. Although routine monitoring for CMV is not recommended, the possibility of a CMV reactivation should be considered in patients with MM treated with daratumumab and infectious symptoms that cannot otherwise be explained. (C) 2018 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据